SEC Form 4 · accession 0001209191-16-121339
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul L Jenkinson
Officer — Chief Financial Officer
Period of report
May 16, 2016
Accepted (ET)
May 18, 2016 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $45.04 | May 16, 2016 | A | 125,000 | A | — | May 15, 2026 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date identified in column 3, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.